OBJECTIVE: To identify a novel serum biomarker of disease activity in inflammatory autoimmune disorders. METHODS: Sera obtained from rheumatoid arthritis (RA) patients before and after anti-TNF therapy were analysed by iTRAQ (isobaric tags for relative and absolute quantitation) quantitative proteomic analysis and further validated by ELISA. RESULTS: Of 326 proteins identified by proteomic analysis, increased serum levels of leucine-rich alpha-2 glycoprotein (LRG) was identified in RA patients before therapy. Serum LRG concentrations were significantly elevated in RA patients compared with healthy controls and decreased after anti-TNF therapy. Furthermore, serum LRG concentrations correlated with disease activity in RA and Crohn's disease (CD). Interestingly, in a subpopulation of patients with active CD and normal C-reactive protein levels, serum LRG concentrations were elevated. CONCLUSIONS: LRG represents a novel serum biomarker for monitoring disease activity during therapy in autoimmune patients, particularly useful in patients with active disease but normal CRP levels.
OBJECTIVE: To identify a novel serum biomarker of disease activity in inflammatory autoimmune disorders. METHODS: Sera obtained from rheumatoid arthritis (RA) patients before and after anti-TNF therapy were analysed by iTRAQ (isobaric tags for relative and absolute quantitation) quantitative proteomic analysis and further validated by ELISA. RESULTS: Of 326 proteins identified by proteomic analysis, increased serum levels of leucine-rich alpha-2 glycoprotein (LRG) was identified in RApatients before therapy. Serum LRG concentrations were significantly elevated in RApatients compared with healthy controls and decreased after anti-TNF therapy. Furthermore, serum LRG concentrations correlated with disease activity in RA and Crohn's disease (CD). Interestingly, in a subpopulation of patients with active CD and normal C-reactive protein levels, serum LRG concentrations were elevated. CONCLUSIONS:LRG represents a novel serum biomarker for monitoring disease activity during therapy in autoimmune patients, particularly useful in patients with active disease but normal CRP levels.
Authors: Jon J Ladd; Tina Busald; Melissa M Johnson; Qing Zhang; Sharon J Pitteri; Hong Wang; Dean E Brenner; Paul D Lampe; Raju Kucherlapati; Ziding Feng; Ross L Prentice; Samir M Hanash Journal: Cancer Prev Res (Phila) Date: 2012-01-25
Authors: Jayme L Wiederin; Robert M Donahoe; James R Anderson; Fang Yu; Howard S Fox; Howard E Gendelman; Pawel S Ciborowski Journal: J Proteome Res Date: 2010-09-03 Impact factor: 4.466
Authors: Quan Hong; Lu Zhang; Jia Fu; Divya A Verghese; Kinsuk Chauhan; Girish N Nadkarni; Zhengzhe Li; Wenjun Ju; Matthias Kretzler; Guang-Yan Cai; Xiang-Mei Chen; Vivette D D'Agati; Steven G Coca; Detlef Schlondorff; John C He; Kyung Lee Journal: J Am Soc Nephrol Date: 2019-03-11 Impact factor: 10.121